deltatrials
Completed PHASE3 NCT00235859

Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Human Anti-TNF Antibody Adalimumab Administered as Subcutaneous Injections in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate

Sponsor: Abbott

Conditions Rheumatoid Arthritis
Interventions adalimumab methotrexate
Updated 5 times since 2017 Last updated: Aug 28, 2007 Started: Jul 31, 2003

Listed as NCT00235859, this PHASE3 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Abbott, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abbott
  • Eisai Limited
Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.